

# Shancheng Ren

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2014960/publications.pdf>

Version: 2024-02-01

63  
papers

4,731  
citations

159585

30  
h-index

110387

64  
g-index

67  
all docs

67  
docs citations

67  
times ranked

7886  
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy. <i>Clinical Cancer Research</i> , 2022, 28, 552-567.	7.0	25
2	Transvesical Single-Port Robotic Radical Prostatectomy on da Vinci Si: A Safe Access for Patients with Previous Open Surgery for Rectal Cancer. <i>Videourology (New Rochelle, N Y)</i> , 2022, 36, .	0.1	2
3	Super-veil nerve-sparing extraperitoneal pure single-port robotic-assisted radical prostatectomy on da Vinci Si robotic system. <i>World Journal of Urology</i> , 2022, , 1.	2.2	3
4	OTUD6A promotes prostate tumorigenesis via deubiquitinating Brg1 and AR. <i>Communications Biology</i> , 2022, 5, 182.	4.4	10
5	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	17.1	40
6	Extended Focal Ablation of Localized Prostate Cancer With High-Frequency Irreversible Electroporation. <i>JAMA Surgery</i> , 2022, 157, 693.	4.3	16
7	Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. <i>EMBO Molecular Medicine</i> , 2021, 13, e12798.	6.9	59
8	Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. <i>Nature Cell Biology</i> , 2021, 23, 87-98.	10.3	209
9	An acetyl-histone vulnerability in PI3K/AKT inhibition-resistant cancers is targetable by both BET and HDAC inhibitors. <i>Cell Reports</i> , 2021, 34, 108744.	6.4	17
10	SEMA3A-mediated crosstalk between prostate cancer cells and tumor-associated macrophages promotes androgen deprivation therapy resistance. <i>Cellular and Molecular Immunology</i> , 2021, 18, 752-754.	10.5	16
11	CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer. <i>Nature Communications</i> , 2021, 12, 1781.	12.8	32
12	SARS-CoV-2 effects in the genitourinary system and prospects of sex hormone therapy. <i>Asian Journal of Urology</i> , 2021, 8, 303-314.	1.2	13
13	The previously uncharacterized lncRNA APP promotes prostate cancer progression by acting as a competing endogenous RNA. <i>International Journal of Cancer</i> , 2020, 146, 475-486.	5.1	27
14	Assessing the safety and feasibility of neoadjuvant hormone and radiation therapy followed by robot-assisted radical prostatectomy for treating locally advanced prostate cancer: protocol for an open-label, dose-escalation, single-centre, phase I clinical trial. <i>BMJ Open</i> , 2020, 10, e038678.	1.9	1
15	&lt;p&gt;Multiple Expression Assessments of ACE2 and TMPRSS2 SARS-CoV-2 Entry Molecules in the Urinary Tract and Their Associations with Clinical Manifestations of COVID-19&lt;p&gt;. <i>Infection and Drug Resistance</i> , 2020, Volume 13, 3977-3990.	2.7	31
16	Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression. <i>Molecular Therapy</i> , 2020, 28, 2473-2487.	8.2	33
17	LINC00675 activates androgen receptor axis signaling pathway to promote castration-resistant prostate cancer progression. <i>Cell Death and Disease</i> , 2020, 11, 638.	6.3	26
18	A genomic and epigenomic atlas of prostate cancer in Asian populations. <i>Nature</i> , 2020, 580, 93-99.	27.8	183

#	ARTICLE	IF	CITATIONS
19	Regression of castration-resistant prostate cancer by a novel compound QW07 targeting androgen receptor N-terminal domain. <i>Cell Biology and Toxicology</i> , 2020, 36, 399-416.	5.3	11
20	Robotic Perineal Radical Prostatectomy: Initial Experience with the da Vinci Si Robotic System. <i>Urologia Internationalis</i> , 2020, 104, 710-715.	1.3	12
21	Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 134, 29-40.	2.8	22
22	Single-port transperitoneal robotic-assisted laparoscopic radical prostatectomy (spRALP): Initial experience. <i>Asian Journal of Urology</i> , 2019, 6, 294-297.	1.2	12
23	Upregulation of Scavenger Receptor B1 Is Required for Steroidogenic and Nonsteroidogenic Cholesterol Metabolism in Prostate Cancer. <i>Cancer Research</i> , 2019, 79, 3320-3331.	0.9	33
24	Microvesicles and chemokines in tumor microenvironment: mediators of intercellular communications in tumor progression. <i>Molecular Cancer</i> , 2019, 18, 50.	19.2	108
25	Neurotensin and its receptors mediate neuroendocrine transdifferentiation in prostate cancer. <i>Oncogene</i> , 2019, 38, 4875-4884.	5.9	27
26	Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer. <i>BMC Genomics</i> , 2019, 20, 146.	2.8	73
27	Prostate Cancer-associated SPOP mutations enhance cancer cell survival and docetaxel resistance by upregulating Caprin1-dependent stress granule assembly. <i>Molecular Cancer</i> , 2019, 18, 170.	19.2	79
28	SPOP Promotes Nanog Destruction to Suppress Stem Cell Traits and Prostate Cancer Progression. <i>Developmental Cell</i> , 2019, 48, 329-344.e5.	7.0	53
29	Metabolomics and transcriptomics profiles reveal the dysregulation of the tricarboxylic acid cycle and related mechanisms in prostate cancer. <i>International Journal of Cancer</i> , 2018, 143, 396-407.	5.1	57
30	Stromal Gene Expression is Predictive for Metastatic Primary Prostate Cancer. <i>European Urology</i> , 2018, 73, 524-532.	1.9	60
31	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. <i>European Urology</i> , 2018, 73, 322-339.	1.9	130
32	Cyclin D $\alpha$ -CDK4 kinase destabilizes PD-L1 via cullin 3 $\beta$ -SPOP to control cancer immune surveillance. <i>Nature</i> , 2018, 553, 91-95.	27.8	660
33	How can plasma RNA be used to diagnose prostate cancer?. <i>Expert Review of Anticancer Therapy</i> , 2017, 17, 5-7.	2.4	1
34	RED-ML: a novel, effective RNA editing detection method based on machine learning. <i>GigaScience</i> , 2017, 6, 1-8.	6.4	29
35	Intrinsic BET inhibitor resistance in SPOP-mutated prostate cancer is mediated by BET protein stabilization and AKT $\alpha$ -mTORC1 activation. <i>Nature Medicine</i> , 2017, 23, 1055-1062.	30.7	225
36	Dysregulation of INF2-mediated mitochondrial fission in SPOP-mutated prostate cancer. <i>PLoS Genetics</i> , 2017, 13, e1006748.	3.5	54

#	ARTICLE	IF	CITATIONS
37	A first-in-human phase 1 study of proxalutamide (GT0918), a dual MOA androgen receptor blocker in patients with advanced CRPC. <i>Journal of Clinical Oncology</i> , 2017, 35, e16511-e16511.	1.6	0
38	Nomograms for predicting Gleason upgrading in a contemporary Chinese cohort receiving radical prostatectomy after extended prostate biopsy: development and internal validation. <i>Oncotarget</i> , 2016, 7, 17275-17285.	1.8	10
39	Integration of lipidomics and transcriptomics unravels aberrant lipid metabolism and defines cholesteryl oleate as potential biomarker of prostate cancer. <i>Scientific Reports</i> , 2016, 6, 20984.	3.3	103
40	Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer. <i>Cell Reports</i> , 2016, 15, 599-610.	6.4	101
41	Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 416.e1-416.e7.	1.6	33
42	A feed-forward regulatory loop between androgen receptor and PlncRNA-1 promotes prostate cancer progression. <i>Cancer Letters</i> , 2016, 374, 62-74.	7.2	64
43	Integration of Metabolomics and Transcriptomics Reveals Major Metabolic Pathways and Potential Biomarker Involved in Prostate Cancer. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 154-163.	3.8	149
44	Epigenetic Pattern on the Human Y Chromosome Is Evolutionarily Conserved. <i>PLoS ONE</i> , 2016, 11, e0146402.	2.5	11
45	The older the better: The characteristic of localized prostate cancer in Chinese men. <i>Asian Journal of Urology</i> , 2015, 2, 129-132.	1.2	1
46	SPOP E3 Ubiquitin Ligase Adaptor Promotes Cellular Senescence by Degrading the SENP7 deSUMOylase. <i>Cell Reports</i> , 2015, 13, 1183-1193.	6.4	55
47	Percent free prostate-specific antigen for prostate cancer diagnosis in Chinese men with a PSA of 4.0-10.0 ng/mL: Results from the Chinese Prostate Cancer Consortium. <i>Asian Journal of Urology</i> , 2015, 2, 107-113.	1.2	6
48	Clinical utility of a novel urine-based gene fusion TTTY15-USP9Y in predicting prostate biopsy outcome. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 384.e9-384.e20.	1.6	25
49	Large-scale association analysis in Asians identifies new susceptibility loci for prostate cancer. <i>Nature Communications</i> , 2015, 6, 8469.	12.8	51
50	Truncated ERG Oncoproteins from TMPRSS2-ERG Fusions Are Resistant to SPOP-Mediated Proteasome Degradation. <i>Molecular Cell</i> , 2015, 59, 904-916.	9.7	129
51	Age-Specific Cutoff Value for the Application of Percent Free Prostate-Specific Antigen (PSA) in Chinese Men with Serum PSA Levels of 4.0-10.0 ng/ml. <i>PLoS ONE</i> , 2015, 10, e0130308.	2.5	14
52	Identification of specific DNA methylation sites on the Y-chromosome as biomarker in prostate cancer. <i>Oncotarget</i> , 2015, 6, 40611-40621.	1.8	17
53	Development and prospective multicenter evaluation of the long noncoding RNA MALAT-1 as a diagnostic urinary biomarker for prostate cancer. <i>Oncotarget</i> , 2014, 5, 11091-11102.	1.8	160
54	Prostate cancer in Asia: A collaborative report. <i>Asian Journal of Urology</i> , 2014, 1, 15-29.	1.2	136

#	ARTICLE	IF	CITATIONS
55	Histone H4 Lys 20 methyltransferase SET8 promotes androgen receptor-mediated transcription activation in prostate cancer. <i>Biochemical and Biophysical Research Communications</i> , 2014, 450, 692-696.	2.1	34
56	Establishment of a Chinese bladder cancer cell line (T921) with high metastatic activity. <i>In Vitro Cellular and Developmental Biology - Animal</i> , 2013, 49, 668-678.	1.5	2
57	Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. <i>European Journal of Cancer</i> , 2013, 49, 2949-2959.	2.8	287
58	Long Noncoding RNA MALAT-1 is a New Potential Therapeutic Target for Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2013, 190, 2278-2287.	0.4	292
59	Genome-wide association studies on prostate cancer: the end or the beginning?. <i>Protein and Cell</i> , 2013, 4, 677-686.	11.0	11
60	The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 1117-1123.	1.6	174
61	Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes. <i>Prostate</i> , 2013, 73, 1824-1835.	2.3	29
62	Oncogenic CUL4A determines the response to thalidomide treatment in prostate cancer. <i>Journal of Molecular Medicine</i> , 2012, 90, 1121-1132.	3.9	45
63	RNA-seq analysis of prostate cancer in the Chinese population identifies recurrent gene fusions, cancer-associated long noncoding RNAs and aberrant alternative splicings. <i>Cell Research</i> , 2012, 22, 806-821.	12.0	352